Objective: Coronavirus Diease-2019 (COVID-19) is a pandemic outbreak in the world and is the leading cause of
Severe Acute Respiratory Syndrome (SARS).
Methods: Currently, many drugs/therapies have been tested for COVID-19 which responded sub optimally to the patients.
Remdesivir is a RNA polymerase inhibitor found promising results in ongoing clinical trials and shows faster recovery rate
in COVID-19 patients. Currently, USFDA approves for emergent use of this drug in severe COVID-19 patients.
Results: In this review, we discussed brief overview of biopharmaceutical and pharmacological aspects of Remdesivir.
Moreover, ongoing regulatory status of Remdesivir by official bodies has also been described.